Amgen Reports Five-Year TOWER Data for Blincyto in Relapsed/Refractory ALL

Amgen today presented five-year overall survival data from the Phase 3 TOWER trial evaluating Blincyto (blinatumomab) versus standard of care chemotherapy in patients with relapsed or refractory B-cell acute lymphoblastic leukemia. The data showed that 23% of patients in the Blincyto arm were alive at five years compared to 12% in the chemotherapy arm.